Showing results (91-100 of 110) with videos related to

Sort By:
Pageof 11
European Journal of Cancer (Oxford, England : 1990)|April 15, 2018
Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patientsE Jacquet, A Lardy-Cléaud, B Pistilli, et al.
ESMO Open|September 18, 2025
Real-world treatment patterns and effectiveness after disease progression on CDK4/6 inhibitors for HR-positive/HER2-negative metastatic breast cancer in the ESME-MBC cohortR Varnier, D Pérol, W Jacot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 29, 2024
Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): pilot study with 18F-fluoroestradiol (18F-FES) CT/PETA Gennari, E Brain, A De Censi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2020
An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45V Bjelic-Radisic, F Cardoso, D Cameron, et al.
European Journal of Cancer (Oxford, England : 1990)|February 18, 2014
Risk estimations and treatment decisions in early stage breast cancer: agreement among oncologists and the impact of the 70-gene signatureC A Drukker, H C van den Hout, G S Sonke, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 18, 2025
Palbociclib plus letrozole versus weekly paclitaxel, both in combination with trastuzumab plus pertuzumab, as neoadjuvant treatment for patients with HR-positive/HER2-positive early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17)L Malorni, S Tyekucheva, A Gombos, et al.
Nature Genetics|March 8, 2011
Mutations in NOTCH2 cause Hajdu-Cheney syndrome, a disorder of severe and progressive bone lossMichael A Simpson, Melita D Irving, Esra Asilmaz, et al.
ESMO Open|March 27, 2026
The ESMO/SIOG Cancer in the Elderly Working Group pragmatic strategies for clinical trial designs and endpoints in older adults with cancerC Baldini, A R A Mislang, K-L Cheung, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2020
Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutationsJ Mazieres, C Cropet, L Montané, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 21, 2016
Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational studyS Delaloge, D Pérol, C Courtinard, et al.
Pageof 11